SHANGHAI., Sept. 18, 2020 – On Sept. 18, Ernst & Young and Fudan University School of Management hosted China’s Most Promising Company Award Ceremony 2020 in Shanghai. During the award ceremony, Keya Medical was recognized as the winner of China’s Most Promising Company award because of its leading R&D team and innovative cardiovascular product line.
Since 2016, Keya Medical has been committed to using AI to develop software medical devices that enable healthcare delivery organizations to provide better patient care. Earlier this year, Keya Medical became the first medical imaging AI company in China to receive regulatory approval for a Class III AI medical device. DEEPVESSEL FFR, the only CT-FFR product approved for clinical use in China, uses deep learning technology to non-invasively perform a physiological functional assessment of the coronary arteries using coronary CT angiography scans. The company is continuing to develop products using deep learning that can be used in the diagnosis and treatment of patients with cardiovascular diseases.
About Keya Medical
Keya Medical Technology Co. Ltd. is a medical technology manufacturer that develops artificial intelligence applications that enable healthcare delivery organizations to provide better patient care. Since 2016, the company has combined advanced deep learning algorithms with other technologies to provide accurate diagnosis and treatment solutions to medical institutions around the world. Today, Keya Medical has partnered with over 200 healthcare systems around the world, and the company’s products are used in Chinese hospitals, coronary catheterization labs, and imaging centers. To learn more about Keya Medical, follow us on LinkedIn and Twitter.